Bell Potter has a buy rating and $34.00 price target on its shares. This suggests that upside of 20% is possible from current levels. Goldman Sachs has just initiated coverage on ResMed and named it ...
Here's why brokers are feeling bullish about these three shares this week. The post Brokers name 3 ASX shares to buy today ...
The note reveals that Goldman has initiated coverage with a buy rating and $48.90 price target on ResMed's shares. Based on ...
Goldman Sachs initiated coverage on ResMed Inc (NYSE:RMD) with a "Buy" rating and a price target of A$48.9, driven by strong growth prospects in its continuous airway pressure (CPAP) therapy segment.
Goldman Sachs initiated coverage of ResMed (RMD) with a Buy rating and A$48.90 price target The firm says its Buy thesis is based on “robust” ...
The latest edition of STAT’s Health Tech newsletter brings you important dispatches from the J.P. Morgan Health Care ...